S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden’s $374B Giveaway Into This Sector (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
My biggest AI fear (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
He Is Giving Away Bitcoin (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden’s $374B Giveaway Into This Sector (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
My biggest AI fear (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
He Is Giving Away Bitcoin (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden’s $374B Giveaway Into This Sector (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
My biggest AI fear (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
He Is Giving Away Bitcoin (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Biden’s $374B Giveaway Into This Sector (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
My biggest AI fear (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
He Is Giving Away Bitcoin (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Free Trial
OTCMKTS:ALPMY

Astellas Pharma (ALPMY) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free ALPMY Stock Alerts
$9.50
+0.03 (+0.32%)
(As of 04/19/2024 ET)
Compare
Today's Range
$9.48
▼
$9.64
50-Day Range
$9.27
▼
$11.15
52-Week Range
$9.15
▼
$16.91
Volume
1.00 million shs
Average Volume
288,421 shs
Market Capitalization
$17.19 billion
P/E Ratio
24.26
Dividend Yield
3.58%
Price Target
N/A
Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest
ALPMY stock logo

About Astellas Pharma Stock (OTCMKTS:ALPMY)

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

ALPMY Stock Price History

ALPMY Stock News Headlines

April 15, 2024 | finance.yahoo.com
U.S. Stocks Erase Early Gains
April 15, 2024 | finance.yahoo.com
Stocks Lose Steam to Start Week; Goldman Rises After Earnings
April 19, 2024 | Crypto 101 Media (Ad)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
April 15, 2024 | finance.yahoo.com
Stock Futures Up With Goldman Earnings in Focus
April 12, 2024 | americanbankingnews.com
Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Up 53.1% in March
April 4, 2024 | morningstar.com
Astellas Pharma Inc ADR
March 29, 2024 | msn.com
China NMPA accepts Astellas’ sBLA for urothelial cancer treatment
March 28, 2024 | markets.businessinsider.com
Astellas & Pfizer's SBLA For Enfortumab Vedotin With Keytruda Gets Approval In China
April 19, 2024 | Crypto 101 Media (Ad)
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
March 28, 2024 | finance.yahoo.com
China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for enfortumab vedotin with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer
March 26, 2024 | finanznachrichten.de
Astellas Pharma Inc.: Astellas' VYLOY (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
March 26, 2024 | finanznachrichten.de
Astellas Pharma Receives Permanent J-code for IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy
March 26, 2024 | finance.yahoo.com
Astellas' VYLOY™ (zolbetuximab) Approved in Japan for Treatment of Gastric Cancer
March 26, 2024 | finance.yahoo.com
Astellas Receives Permanent J-code for IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
March 22, 2024 | prnewswire.com
Astellas Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting
March 20, 2024 | finance.yahoo.com
Q4 2023 Taysha Gene Therapies Inc Earnings Call
March 11, 2024 | finance.yahoo.com
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
March 11, 2024 | businesswire.com
Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics
March 3, 2024 | prnewswire.com
Astellas Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan
February 15, 2024 | finance.yahoo.com
PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) Granted Priority Review by Japan's Ministry of Health, Labour and Welfare for First-Line Treatment of Advanced Bladder Cancer
February 15, 2024 | finance.yahoo.com
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
February 15, 2024 | prnewswire.com
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
February 7, 2024 | finance.yahoo.com
Astellas Makes Announcement about Management Structure
February 1, 2024 | finance.yahoo.com
Astellas to Air New VEOZAH® (fezolinetant) TV Spot During the Super Bowl
January 31, 2024 | markets.businessinsider.com
Astellas Submits SNDA In Japan For PADCEV-KEYTRUDA For Advanced Bladder Cancer Treatment
January 31, 2024 | markets.businessinsider.com
Astellas Pharma Announces Collaboration With Mass General Brigham
January 31, 2024 | finance.yahoo.com
Astellas Submits Supplemental New Drug Application in Japan for PADCEV™ (enfortumab vedotin (genetical recombination)) with KEYTRUDA® (pembrolizumab (genetical recombination)) for First-Line Treatment of Advanced Bladder Cancer
See More Headlines
Receive ALPMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Astellas Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/05/2024
Today
4/19/2024
Fiscal Year End
3/31/2025
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:ALPMY
CUSIP
N/A
CIK
1446390
Web
www.astellas.com
Phone
(133) 244-3000
Fax
N/A
Employees
14,484
Year Founded
1923

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
24.26
Forward P/E Ratio
41.30
P/E Growth
1.36
Net Income
$742 million
Net Margins
0.08%
Pretax Margin
N/A
Return on Equity
6.39%
Return on Assets
3.29%

Debt

Debt-to-Equity Ratio
0.31
Current Ratio
0.91
Quick Ratio
0.71

Sales & Book Value

Annual Sales
$11.24 billion
Price / Sales
1.53
Cash Flow
$1.36 per share
Price / Cash Flow
6.97
Book Value
$6.27 per share
Price / Book
1.52

Miscellaneous

Outstanding Shares
1,809,660,000
Free Float
N/A
Market Cap
$17.19 billion
Optionable
Not Optionable
Beta
0.32

Social Links

5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Naoki Okamura BSc (Age 62)
    President, CEO & Director
    Comp: $961.41k
  • Mr. Atsushi Kitamura
    Chief Financial Officer
  • Nobue Yasuda
    General Manager of Finance & Accounting Department
  • Mr. Yoshitsugu Shitaka Ph.D.
    Chief Scientific Officer & Senior Managing Executive Officer
  • Ms. Catherine B. Levitt
    General Counsel
  • Mr. Katsuyoshi Sugita (Age 57)
    Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director
  • Mr. Stig Ogata
    Vice President of Corporate Communications
  • Ms. Collette Taylor (Age 61)
    Senior Vice President of Human Resources
  • Ms. Tatjana Dragovic
    Senior VP and Head of Ethics & Compliance
  • Mr. Nobuaki Tanaka
    President of Japan Commercial & Senior Corporate Executive

Key Competitors

View All Competitors

Should I Buy Astellas Pharma Stock? ALPMY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Astellas Pharma Inc.:

  • Astellas Pharma Inc. has a diverse portfolio of pharmaceutical products, including XTANDI for prostate cancer, XOSPATA for acute myeloid leukemia, and PADCEV for urothelial cancer, which can provide stable revenue streams.
  • The company has shown resilience in the market with a market capitalization of $19.45 billion, indicating a strong presence and stability in the industry.
  • Astellas Pharma's recent quarterly earnings report showed a positive EPS of $0.12, demonstrating financial growth and potential for investors.
  • With a low debt-to-equity ratio of 0.31, Astellas Pharma has a healthy balance sheet, reducing financial risk for investors.
  • The stock price of Astellas Pharma has shown stability and potential for growth, making it an attractive investment opportunity.

Cons

Investors should be bearish about investing in Astellas Pharma Inc. for these reasons:

  • Despite positive aspects, the company operates in a highly competitive industry, which may pose challenges for sustained growth and market share.
  • Astellas Pharma's stock price has experienced fluctuations, indicating potential volatility in the market that could impact investor returns.
  • The company's price-to-earnings ratio of 28.05 and price-to-earnings-growth ratio of 2.66 may suggest that the stock is currently overvalued, potentially limiting short-term gains for investors.
  • There has been a recent increase in short interest in Astellas Pharma, which could indicate market sentiment leaning towards a bearish outlook on the stock.
  • Investors should consider the potential impact of regulatory changes or developments in the pharmaceutical industry on Astellas Pharma's operations and financial performance.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 12, 2024. Please send any questions or comments about these Astellas Pharma pros and cons to contact@marketbeat.com.

ALPMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Astellas Pharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALPMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALPMY, but not buy additional shares or sell existing shares.
View ALPMY analyst ratings or view top-rated stocks.

How have ALPMY shares performed in 2024?

Astellas Pharma's stock was trading at $11.90 at the start of the year. Since then, ALPMY stock has decreased by 20.2% and is now trading at $9.50.
View the best growth stocks for 2024 here.

Are investors shorting Astellas Pharma?

Astellas Pharma saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 171,800 shares, an increase of 53.1% from the March 15th total of 112,200 shares. Based on an average daily volume of 545,200 shares, the days-to-cover ratio is presently 0.3 days.
View Astellas Pharma's Short Interest.

How were Astellas Pharma's earnings last quarter?

Astellas Pharma Inc. (OTCMKTS:ALPMY) released its quarterly earnings results on Monday, February, 5th. The company reported $0.12 EPS for the quarter. The business earned $2.86 billion during the quarter. Astellas Pharma had a trailing twelve-month return on equity of 6.39% and a net margin of 0.08%.

Is Astellas Pharma a good dividend stock?

Astellas Pharma (OTCMKTS:ALPMY) pays an annual dividend of $0.34 per share and currently has a dividend yield of 3.55%.

When did Astellas Pharma's stock split?

Astellas Pharma shares split before market open on Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly minted shares were issued to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

How do I buy shares of Astellas Pharma?

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Astellas Pharma have any subsidiaries?
The following companies are subsidiares of Astellas Pharma: Agensys, Astellas B.V, Astellas Farma Brasil Importaçáo e Distribuiçáo de Medicamentos Ltda., Astellas Farma Colombia SAS, Astellas Farma Limitada, Astellas Green Supply Inc., Astellas Innovation Management LLC, Astellas Institute for Regenerative Medicine, Astellas Ireland Co. Limited, Astellas Pharma, Astellas Pharma A.G., Astellas Pharma A/S, Astellas Pharma Australia Pty Ltd., Astellas Pharma B.V., Astellas Pharma Canada Inc., Astellas Pharma China Inc., Astellas Pharma Co. Limited, Astellas Pharma DMCC, Astellas Pharma Europe B.V., Astellas Pharma Europe Ltd., Astellas Pharma Ges.m.b.H, Astellas Pharma Global Development Inc., Astellas Pharma GmbH, Astellas Pharma Hong Kong Co. Ltd., Astellas Pharma India Private Limited, Astellas Pharma Kft., Astellas Pharma Korea Inc., Astellas Pharma Ltd., Astellas Pharma Malaysia Sdn. Bhd., Astellas Pharma Philippines Inc., Astellas Pharma S.A., Astellas Pharma S.A.S, Astellas Pharma S.p.A., Astellas Pharma Singapore Pte. Ltd., Astellas Pharma Sp.zo.o., Astellas Pharma Taiwan Inc., Astellas Pharma Tech Co. Ltd., Astellas Pharma US Inc., Astellas Pharma d.o.o., Astellas Pharma ilaç Ticaret ve Sanayi A.Ş., Astellas Pharma s.r.o, Astellas Pharmaceuticals AEBE, Astellas Research Institute of America LLC, Astellas US Holding Inc., Astellas US LLC, Astellas US Technologies Inc., Astellas Venture Management LLC, Audentes Therapeutics, Ganymed Pharmaceuticals, Iota Biosciences, JSC Astellas Pharma, Mitobridge, Nanna Therapeutics, OSI Pharmaceuticals, Ocata Therapeutics, Ogeda, P.T. Astellas Pharma Indonesia, Potenza Therapeutics, Quethera, The Representative Office of Astellas Pharma Singapore Pte. Ltd. in Vietnam, Universal Cells Inc., and Xyphos.
Read More
This page (OTCMKTS:ALPMY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
SHOCKING Crypto Leak…
Crypto 101 Media
Man Who Predicted 2008: “This Will be Worse.”
Altimetry
Fed launches fourth dollar overhaul
Stansberry Research